Esperion climbs after patent win over Dr. Reddy’s cholesterol drugs

** Shares of drugmaker Esperion ESPR rise 6.5% to $3.09

** ESPR says it has reached a settlement with India-based Dr. Reddy’s Laboratories that will prevent the latter from selling generic versions of its cholesterol drugs Nexletol and Nexlizet in the U.S. before April 2040

** The deal resolves a patent lawsuit filed by Esperion after Dr. Reddy’s sought approval to launch generic versions before the patents expired

** Esperion has already settled similar disputes earlier this year with Micro Labs, Hetero USA, and Accord Healthcare over generic versions of Nexletol

** As of last close, stock up 32% YTD